An old but still good friend: chemoimmunotherapy in HCL
Abstract
In this issue of Blood, Schroeder et al 1 from the Kreitman team at the National Cancer Institute build on their already strong track record in clinical research on hairy cell leukemia (HCL) by reporting valuable prospective data on 2 chemoimmunotherapy regimens, DCFR (pentostatin [alias deoxycoformycin (DCF)] plus rituximab) and BR (bendamustine + rituximab), for patients with relapsed or refractory (R/R) HCL.
Fields of Study & Subjects
Chronic Lymphocytic Leukemia Research
Lymphoma Diagnosis and Treatment
Viral-associated cancers and disorders
Publication details
- Journal / source
- Blood
- Publisher
- American Society of Hematology
- Volume
- 147
- Issue
- 7
- Pages
- 705–707
- Publication date
- 12 February 2026
- Language
- EN